PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Tested for efficacy as a laxative in a multicenter randomized controlled trial [PMID:2203870]
Women receiving C. alata tea had shorter times to first passage of flatus and first defecation compared to controls [PMID:31779993]
Extract demonstrated comparable efficacy to albendazole, with a dosage of 500 mg/ml inducing faster paralysis and death [PMID:39360533]
Leaf extract reduced oocyst output and ameliorated necrotic enteritis and inflammatory changes in the jejunum [PMID:38845567, PMID:42082794]
Ethyl acetate and n-hexane fractions showed concentration-dependent antifungal activity [PMID:38543166]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 32685725 (2020) — Chemical constituents, usage and pharmacological activity of Cassia alata. · Heliyon
- 2.PMID: 39360533 (2025) — Cassia alata: Helminth and Bacteria Fighter. · Combinatorial chemistry & high throughput screening
- 3.PMID: 27538998 (2016) — A Review of Flavonoids from Cassia Species and their Biological Activity. · Current pharmaceutical biotechnology
- 4.PMID: 39381590 (2024) — Review on Cassia alata Bioactive Compounds: In silico, in vitro, and in vivo Studies. · Drug design, development and therapy
- 5.PMID: 40709743 (2025) — Real World Case Series: A.G.E. Interrupter Ultra Serum. · Journal of cosmetic dermatology